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Abstract
This review reports on the development of patient-reported outcome measures (PROMs), published within the past ten
years, for people with multiple sclerosis (PwMS). Moreover, this review evaluates the extent to which patient
participation was integrated in the development of the PROMs. A systematic review was conducted, and four relevant
articles were extracted, from which nine PROMs were identified. Patient involvement in the development phase was
identified in three PROMs. The results emphasize the need for more patient involvement in the development of new
MS-specific PROMs to ensure that the measures reflect the needs and priorities of PwMS.
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Introduction
Multiple Sclerosis (MS) is an autoimmune,
neurodegenerative chronic disease of the central nervous
system.1 People with MS (PwMS) develop perivenular
inflammatory lesions that cause demyelinating plaque. The
symptomatology of MS results from a combination of the
location and size of these lesions.1 MS is a complex disease
with a fluctuating symptom burden, and each patient has a
unique disease course. Consequently, people with MS
(PwMS) experience a range of symptoms that vary in
severity, affect their quality of life and cause significant
disability over time.2
The treatment of MS entails a combination of diseasemodifying and symptomatic treatment options that are
sometimes supplemented with complementary and
alternative treatments and exercise and/or rehabilitation.3
Patient-reported outcome measures (PROMs) measure
patients’ assessment of their state of health, symptoms,
health-related quality of life and functional level.4 The
perspectives of patients obtained through PROMs are
considered to be valuable for more comprehensive
assessments of health status and the ability to adjust
treatment and patient support accordingly.5, 6 The complex
disease manifestations of MS make PROMs even more
pertinent and also render the development of relevant
PROMs that can capture all aspects of the health status of
PwMS more challenging.7 Current evidence suggests that
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the views of patients, clinicians and researchers on relevant
and valuable PROMs may differ substantially.5, 6 To
accurately reflect and assess patients’ perceptions of their
health status, their perspectives should be incorporated
into the development process of PROMs.6
This systematic review aims to present the state of the art
of PROMs for PwMS by identifying articles published
within the last ten years that report on the development of
MS-specific PROMs. Furthermore, we aim to explore the
extent to which explicit patient participation was included
in the development phases of these validated MS-specific
PROMs.

Methods
MS-specific PROMs and the degree of patient
participation in the development of these measures were
identified in a systematic literature search according to the
PRISMA statement.8 The search was conducted on
September 3, 2020 in the MEDLINE database via the
PubMed platform, in the Embase database and the
Cochrane library. The search was limited to studies
published during 2011–2020 in English, Danish, Swedish
or Norwegian. Four separate searches were performed on
each database, with a variety of MeSH (medical subject
headings) terms (i.e., multiple sclerosis, patient-reported
outcome, patient outcome assessment, patient
participation, survey/questionnaire) and free search terms.
Search terms were identified based on an initial search of
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Identification

Figure 1. Review process for the identification of PROMs in multiple sclerosis

Records identified
through Pubmed
(N=62)

Records identified through
Cochrane library
(N=42)

Records identified
through Embase
(N=53)

Screening

Records after duplicates
removed
(N=61)

Included

Eligibility

Records screened on title
and abstract
(N=61)

Full-text articles excluded (N=21)

Full-text articles assessed
for eligibility
(N=25)

Studies included in
the review
(N=4)

the literature, and search strategies were developed with
advice from an information retrieval specialist with
expertise in health research and systematic reviews. (Search
strategies can be obtained by contacting the correspondent
author.) Two reviewers selected the articles independently,
with discussions afterwards to avoid discrepancies.
Studies were included if they described a PROM
developed specifically for PwMS. The exclusion criteria
were as follows:
• study population not PwMS
• study does not describe an MS-specific validated
PROMs
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Records excluded
(N=36)

•

Not describing a multiple
sclerosis (MS)-specific,
validated patient reported
outcome measures (PROM)
(N=13)

•

Studies mentioning the use of
PROMs as outcome measure
but with no description of their
development (N=8)

• study mentions the use of PROMs as an outcome
measure but without a description of the
development of the PROM
Explicit evidence of patient participation was explored
using information extracted from the selected articles.

Results
A total of 157 articles were identified and titles and
abstracts of 61 articles were screened, while a full text
review was undertaken for 25 articles, of which 21 were
excluded. The flow diagram in Figure 1 shows the number
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Table 1. PROMs in MS identified from the literature published within the past ten years
PROM instrument

Author, year

Domains

12-item MS Walking
Scale (MSWS-12)

Lejbkowicz et al., 20129

Walking abilities

The Fatigue Severity
Scale (FSS)
Multiple Sclerosis
Quality of Life-54
(MSQoL-54)
Functional Assessment
of MS (FAMS)
The MS Quality-of-Life
Inventory
The Leeds Multiple
Sclerosis Quality of Life
(LMSQoL)
The DYMUS
Questionnaire
MS Quality of Life
(MSQOL)
Patient-Determined
Disease Steps (PDDS)

Lejbkowicz et al., 20129

Fatigue

Evidence of patient
participation
Yes
(Developed based on
interviews with PwMS)
No

Lejbkowicz et al., 20129

Health-related quality of life

No

Lejbkowicz et al., 20129

Health-related quality of life

Lejbkowicz et al., 20129

Health-related quality of life

Yes
(Item generation by PwMS )
No

Lejbkowicz et al, 20129

Health-related quality of life

Solaro et al., 201210

Dysphagia

Yes
(Developed from focus
groups with PwMS)
No

Taheri et al., 201511

Health-related quality of life

No

Learmonth et al., 201312

Disability

No

of articles identified, included or excluded and the reasons
for exclusion at the full-text level.
A total of four articles that represent literature published
during the last ten years were included. Nine MS-specific
validated PROMs were identified in these articles. The
identified articles were scrutinized for explicit evidence of
patient involvement in the development of the PROMs,
and patient contributions to the specific PROM
instruments were evident in three of the nine identified
PROMs. A summary of the MS-specific validated PROMs
and the evidence of contributions by PwMS to their
development is presented in Table 1.

Discussion
In this review, MS-specific PROMs validated for patient
populations with MS were explored with the aim of
updating the state of the art of PROMs, according to
developments during the past decade and gauging the
extent of explicit patient participation in the development
phases.
We identified four articles published within the last ten
years that comment on the development of MS-specific
validated PROMs.9–12 The low number of articles indicates
that the development of new MS-specific PROMs might
have been negligibly small, suggesting that the field of MS
is dominated by older PROMs. Of the nine PROMs found
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in the identified articles, only two (MSWS-12 and PDDS)
were developed within the last ten years. This emphasizes
a development gap and stresses the need for new MSspecific disease outcomes including PROMs that are
validated, feasible in clinical encounters and representative
of new insights into disease development. Within the past
years, the MS treatment paradigm has changed rapidly
from a focus mainly on the effectiveness of disease
modifying therapies measured by the risk of relapses and
Expanded Disability Status Scale (EDSS) score
development to acknowledging that cognition, activities of
daily living, fatigue and, more widely, rehabilitation are
important for many PwMS.13 Furthermore, there is
increasing acknowledgement of the fact that for PwMS
individualized symptomatic treatment options are strongly
linked to quality of life.2, 13, 14
While we identified nine PROMs from the literature
published within the last ten years, Khurana et al.4 found
82 PROMs used in MS to assess symptom burden,
function, quality of life, caregiver burden, treatment
satisfaction and other attributes in their 2017 review of
literature published between 1996 and 2015. Khurana et al.
identified the eight PROMs most commonly used in
clinical trials, namely, MSIS-29, LMSQoL, MSWS-12,
FAMS, HAQUAMS, MUSIQoL, PRIMUS and MSQoL.
Similar to the PROMS identified in this review, the
majority of these had all been developed and validated
prior to 2010. Based on Khurana et al.’s review, it appears
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that the PROMs most commonly used within the field of
MS are developed prior to 2010 and with limited patient
involvement. The present review affirms that the MSspecific PROMs have not evolved much since then, and it
is highly likely that the eight PROMs identified by
Khurana et al. are still most commonly used within the
field of MS. While the development of PROMs has not
progressed, treatments for MS have advanced considerably
over recent years. MS-specific PROMs should reflect the
developments in MS care to be valuable to both patients
and clinicians, which emphasizes the need for the
development of newer MS-specific PROMs.

Conclusion

In recent years, patient involvement in the development of
healthcare services has gained momentum as a key driver
to ensure person-centered, acceptable and accessible
treatments.15, 16 PROMs constitute instruments that
provide an opportunity for patients to contribute
information regarding a range of relevant dimensions that
affect the disease burden, quality of life, treatment
trajectories and patient support. From a patient
perspective, PROMs is an important tool for enhanced
patient involvement. However, the PROMs do not
necessarily reflect the patients’ priorities and perspectives
and may not successfully generate person-centered
outcomes if they are not comprehensive and responsive to
what patients experience with the disease.6, 14
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